Tandem Diabetes Care [TNDM] vs Enovis [ENOV] Detailed Stock Comparison

Tandem Diabetes Care

NASDAQ
Loading...

Enovis

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Tandem Diabetes Care wins in 8 metrics, Enovis wins in 10 metrics, with 0 ties. Enovis appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricTandem Diabetes CareEnovisBetter
P/E Ratio (TTM)-10.01-2.14Tandem Diabetes Care
Price-to-Book Ratio7.450.71Enovis
Debt-to-Equity Ratio340.5656.75Enovis
PEG Ratio-0.15-0.02Tandem Diabetes Care
EV/EBITDA-14.928.97Tandem Diabetes Care
Profit Margin (TTM)-20.51%-37.80%Tandem Diabetes Care
Operating Margin (TTM)-13.24%2.41%Enovis
EBITDA Margin (TTM)N/A2.41%N/A
Return on Equity-111.92%-28.25%Enovis
Return on Assets (TTM)-6.41%0.89%Enovis
Free Cash Flow (TTM)$4.99M$-67.21MTandem Diabetes Care
1-Year Return-59.51%-22.28%Enovis
Price-to-Sales Ratio (TTM)0.990.84Enovis
Enterprise Value$1.13B$3.25BEnovis
EV/Revenue Ratio1.131.49Tandem Diabetes Care
Gross Profit Margin (TTM)52.29%59.29%Enovis
Revenue per Share (TTM)$15$39Enovis
Earnings per Share (Diluted)$-3.08$-14.95Tandem Diabetes Care
Beta (Stock Volatility)1.491.80Tandem Diabetes Care
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Tandem Diabetes Care vs Enovis Stock Performance Analysis

Loading Price Chart...

Tandem Diabetes Care
Enovis
Tandem Diabetes Care Stock Overview | Enovis Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Tandem Diabetes Care2.04%27.31%20.08%-7.63%-10.92%-58.12%
Enovis-2.37%3.58%-0.45%-5.33%-3.82%-29.44%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Tandem Diabetes Care-59.51%-70.67%-87.36%-81.74%-93.13%-93.13%
Enovis-22.28%-30.50%-42.68%-35.29%15.31%-11.39%

News Based Sentiment: Tandem Diabetes Care vs Enovis

Tandem Diabetes Care

News based Sentiment: MIXED

October presented a complex picture for Tandem, with a serious product malfunction investigation unfolding alongside positive regulatory clearances, encouraging insider buying, and solid Q2 revenue growth. These competing factors create significant uncertainty and make it a pivotal month for the company's future trajectory.

View Tandem Diabetes Care News Sentiment Analysis

Enovis

News based Sentiment: POSITIVE

October was a notably positive month for Enovis, marked by significant analyst upgrades, substantial insider buying activity, and a clear strategic direction under its new CEO. These developments suggest growing confidence in the company's future prospects and potential for growth, making it a significant month for investors.

View Enovis News Sentiment Analysis

Performance & Financial Health Analysis: Tandem Diabetes Care vs Enovis

MetricTNDMENOV
Market Information
Market Cap i$1.01B$1.83B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,690,569615,380
90 Day Avg. Volume i1,849,033899,257
Last Close$15.01$31.26
52 Week Range$9.98 - $42.70$25.47 - $49.83
% from 52W High-64.85%-37.27%
All-Time High$302.50 (Jan 13, 2014)$129.72 (Jun 09, 2014)
% from All-Time High-95.04%-75.90%
Growth Metrics
Quarterly Revenue Growth0.09%0.08%
Quarterly Earnings GrowthN/A0.08%
Financial Health
Profit Margin (TTM) i-0.21%-0.38%
Operating Margin (TTM) i-0.13%0.02%
Return on Equity (TTM) i-1.12%-0.28%
Debt to Equity (MRQ) i340.5656.75
Cash & Liquidity
Book Value per Share (MRQ)$1.97$45.11
Cash per Share (MRQ)$4.67$0.77
Operating Cash Flow (TTM) i$9.72M$188.06M
Levered Free Cash Flow (TTM) i$31.96M$65.68M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Tandem Diabetes Care vs Enovis

MetricTNDMENOV
Price Ratios
P/E Ratio (TTM) i-10.01-2.14
Forward P/E i-12.1610.13
PEG Ratio i-0.15-0.02
Price to Sales (TTM) i0.990.84
Price to Book (MRQ) i7.450.71
Market Capitalization
Market Capitalization i$1.01B$1.83B
Enterprise Value i$1.13B$3.25B
Enterprise Value Metrics
Enterprise to Revenue i1.131.49
Enterprise to EBITDA i-14.928.97
Risk & Other Metrics
Beta i1.491.80
Book Value per Share (MRQ) i$1.97$45.11

Financial Statements Comparison: Tandem Diabetes Care vs Enovis

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TNDMENOV
Revenue/Sales i$234.42M$564.55M
Cost of Goods Sold i$116.02M$229.85M
Gross Profit i$118.41M$334.70M
Research & Development i$125.43M$30.70M
Operating Income (EBIT) i$-120.88M$-16.08M
EBITDA i$-116.42M$55.91M
Pre-Tax Income i$-122.09M$-25.65M
Income Tax i$8.47M$10.80M
Net Income (Profit) i$-130.56M$-36.55M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TNDMENOV
Cash & Equivalents i$53.57M$38.46M
Total Current Assets i$663.44M$1.22B
Total Current Liabilities i$288.18M$477.42M
Long-Term Debt i$431.75M$1.42B
Total Shareholders Equity i$155.29M$2.62B
Retained Earnings i$-1.18B$-338.99M
Property, Plant & Equipment i$79.22M$492.24M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TNDMENOV
Operating Cash Flow i$-6.71M$-1.07M
Capital Expenditures i$-6.21M$-43.26M
Free Cash Flow i$-15.70M$-44.86M
Debt Repayment i$-40.76M$-15.44M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTNDMENOV
Shares Short i7.93M6.93M
Short Ratio i4.287.31
Short % of Float i0.16%0.18%
Average Daily Volume (10 Day) i1,690,569615,380
Average Daily Volume (90 Day) i1,849,033899,257
Shares Outstanding i66.26M55.88M
Float Shares i61.82M56.42M
% Held by Insiders i0.01%0.02%
% Held by Institutions i1.20%1.21%

Dividend Analysis & Yield Comparison: Tandem Diabetes Care vs Enovis

MetricTNDMENOV
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A